Labiotech.eu’s Post

Exciting times unfold in the German biotech scene, with familiar companies leading the charge. Rapid evolution fueled by robust investments, exceptional talent, and cutting-edge science catapults the industry onto the global stage. Germany's commitment to innovation has attracted significant investments, propelling it to the forefront of the international biotech arena. Recognizable names signify not only the strength of the German ecosystem but also its potential for global impact. This synergy of investment and talent has laid the foundation for a competitive and vibrant biotech landscape. From local recognition to global limelight, the success of German biotech is a testament to visionary investments and resilient minds. Cheers to the continued success and global influence of the German biotech industry! 🚀🌍🔍 #BiotechInnovation #GlobalImpact #GermanBiotechJourney

💰 7.7 SEK Million is invested in the Swelife-supported Vinnova-project BRIDGE Sweden, gathering key players from Life Science Sweden’s research infrastructure and innovation system. On the agenda:  ✅ Streamline the road from research to commercialization of biological pharmaceuticals and precision medicine.  ✅ Develop new cell lines at SciLifeLab’s DDD platform to bridge the technical gap to Testa Center.  ✅ More closely integrate research infrastructure with the innovation system.    Aimed effects: 📍 Ensure that projects can advance from SciLifeLab to Testa Center for GMP, clinical trials, and manufacturing.  📍 Enhance Sweden's international position and attract foreign small businesses to Sweden for development and subsequent production.  📍Guide projects to the next stage after Testa Center, including structures and support functions.    📣 "BRIDGE's combination of research infrastructure and innovation support, syncing business and technical development on the same platform is, as far as we know, unique”, says Alexandra Patriksson, Science Relations Manager, Testa Center.   📣 ”Our goal is to develop stable cell lines for scaling up, this will also lower the investment threshold for these projects." says Per I Arvidsson, Platform Director, SciLifeLab.   🗓️ Project time: 3 years. 🤝 Project partners: Testa Center, SciLifeLab DDD, STUNS Life science ,the Lund Stem Cell Center and pre-GMP unit at Lunds universitet, ALIS (Association of nine Life Science Incubators in Sweden, GU Ventures, KI Innovations AB, LEAD (Business Incubator), Medeon Science Park & Incubator, Sahlgrenska Science Park, SmiLe Venture Hub, Sting, UIC - Uppsala Innovation Centre, Umeå Biotech Incubator). #lifescience #innovation #commercialization #precisionmedicine

💡 South East Asia's Biotech Surge 💡 The biotech landscape is undergoing a seismic shift, and South East Asia stands at the heart of this transformation. As we witness a global market expansion from USD 17.4 billion in 2023 to an astonishing USD 113.53 billion by 2032, the opportunities for innovation, collaboration, and growth in this region are unprecedented. CellTech Innovation is at the forefront, facilitating the connections and partnerships necessary to harness this exponential growth. 🌏 A Regional Hub for Biotech Innovation South East Asia, with its diverse cultures, booming economies, and rapidly advancing technological capabilities, is becoming a pivotal hub for biotech innovation. This vibrant region offers a fertile ground for biotech ventures, driven by increasing investments, supportive government policies, and a growing talent pool passionate about pushing the boundaries of medical science. 🤝 Forging Strategic Partnerships At CellTech, our mission is to catalyze the potential within this dynamic market. We're building bridges between startups, investors, research institutions, and industry leaders both within the region and globally. Our focus is on creating synergies that not only accelerate scientific discovery and development but also ensure these innovations reach the market, transforming lives and communities. 💼 Tapping into Exponential Growth The projected market growth in South East Asia is not just a number—it's a testament to the region's potential to lead the next wave of biotech breakthroughs. CellTech is your partner in navigating this exciting landscape, offering strategic insights, access to funding, and the expertise needed to thrive in a competitive global market. 🚀 Join the Biotech Revolution with CellTech Whether you're a startup looking to scale, an investor seeking cutting-edge biotech ventures, or a researcher aiming to translate your discoveries into tangible solutions, CellTech is your gateway to success in South East Asia's booming biotech sector. Together, we can ride the wave of biotech innovation, making significant impacts on healthcare worldwide. Don’t miss the opportunity to be part of this thrilling journey of growth and discovery. Join us in shaping the future of biotech in South East Asia and beyond. #BiotechFuture #SEAMarketTrends #CellTechPartnerships https://lnkd.in/gPZc3xfW

Great to catch up with Ron Leuty at San Francisco Business Times at #BIO2024: When Moonwalk Biosciences Inc. CEO Alex Aravanis MD PhD started his presentation at the BIO convention in San Diego earlier this week, he saw a standing-room-only crowd, and after his 15-minute talk he was peppered with questions. In more formal meetings with potential partners, Aravanis faced more questions. "I think there's a lot of people who are curious about (epigenetics)" — how DNA modifications can be passed cell to cell — "curious about the capabilities, how mature it is," Aravanis said. "In the partnering meetings, there're folks who have an immediate use for it, and there are folks who said, 'Look, we reached out to you because we realized this is an exciting new area.'" The ability to spread a company's scientific message with hundreds, if not thousands, of people in a few days is why companies come to the Biotechnology Innovation Organization's annual convention, which closes today in San Diego. More than 20 Bay Area life sciences companies were scheduled among the scores making formal presentations in tiny "theaters" on the convention's exhibit floor, such as South San Francisco's Moonwalk, or in BIO's "Startup Stadium." Read the article (subscription required): https://lnkd.in/eTEdgDEa

As part of our ongoing series of success stories of the o2h Kickstarter winners, we’re excited to showcase the global impact of our initiative. Over the past two years, the 𝐨𝟐𝐡 𝐊𝐢𝐜𝐤𝐬𝐭𝐚𝐫𝐭𝐞𝐫 𝐩𝐫𝐨𝐠𝐫𝐚𝐦 has empowered biotech startups by providing them with the resources, mentorship, and connections needed to turn groundbreaking ideas into real-world progress. As a result, many of these startups have achieved significant milestones, advancing novel therapies and drawing interest from leading biotech and pharma players. One such example is Protai. Protai is revolutionizing drug discovery through its AI-powered proteomics platform, which focuses on disease-related protein changes to accelerate drug development, especially in oncology. Their innovative approach has already garnered substantial attention, including securing $𝟐𝟎𝐌 in seed funding to expand their oncology pipeline. With a vision of leveraging AI-driven insights, Protai is committed to delivering life-changing treatments to patients faster and more effectively - pushing the boundaries of precision medicine. Read: https://lnkd.in/d_VApQpt To further support USA-based biotech start-ups, we recently launched the latest edition of 𝐨𝟐𝐡 𝐊𝐢𝐜𝐤𝐬𝐭𝐚𝐫𝐭𝐞𝐫: 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐞 𝐀𝐦𝐞𝐫𝐢𝐜𝐚. If you want to maximise this opportunity, visit https://lnkd.in/dAxrjKjn or write to us at kickstarter@o2h.com Eran Seger Digital Elevator Altitude Marketing  #AI #Biotech #Proteomics #DrugDiscovery #Oncology #Innovation #Testimonial #o2hKickstarter #ClientStory #SeedingNewIdeas Samba Scientific

June 6, 2024 - OniX: Standardizing Global Preclinical Research for Accelerated Innovation In a world where the US, UK, and EU federal governments collectively spend over $600 billion annually on R&D, the sheer volume of data generated daily is staggering. OniX stands at the forefront of harnessing this wealth of knowledge, serving as the premier research knowledge hub that standardizes preclinical data from universities, startups, biotech companies, accelerators, and incubators. By aggregating both public and proprietary data, OniX empowers strategic R&D and business development activities, accelerating the path from innovation to market. https://lnkd.in/d_bPbcD

📢 Calling all California-based life sciences startups! California Life Sciences (CLS) is thrilled to announce that we are now accepting pitch applications for our exclusive Investor Partnering Forum, taking place just before the highly anticipated Innovation Showcase. This is a unique opportunity for emerging startups to connect with a curated group of investors, each investor selects up to six companies for one-on-one, 20-minute in-person meetings. Confirmed Investors: AbbVie Ventures, Astellas Pharma Venture Management, Boehringer Ingelheim Venture Fund, Chiesi Global Rare Diseases, Civilization Ventures, Remiges Ventures, Inc., Servier Pharmaceuticals, and Xontogeny. At CLS, we are dedicated to advancing the innovation ecosystem in California, fostering growth, and empowering startups in the life sciences sector. If you're ready to accelerate your journey and connect with key investors, apply today! 🔗Learn more & apply: https://bit.ly/4e2sQcR #Innovation #CaliforniaLifeSciences #partneringforum #pitchyourstartup

Bank of Ireland Kernel Capital Growth Fund portfolio Company ALTRATECH LIMITED has been selected to receive up to €10.5m in blended funding from the European Innovation Council Accelerator Program. This investment will allow Altratech to engage in clinical trials on HIV patients combined with significant scale-up in manufacturing and product development over the next three years.  Altratech, led by Dr. Tara Dalton make up part of the 21% of selected companies which are female-led.  Niall Olden, Managing Partner, Kernel & Chairman, Altratech said: "The team at Altratech are exceptional. They have  taken an innovative concept with the potential to be one of the most significant developments in molecular diagnostics in decades, all the way through proof of concept to initial product prototypes. With five families of over 40 patents granted across the EU, US and Asia the company is an exemplar for the commercialisation of research and development." https://lnkd.in/eMQwAEgx #EICAcceleratorProgram #EnterpriseIreland #EUFunding

Meeting a unique team was such an honour! ARTHEx Biotech is an EIC Accelerator beneficiary, based in Spain. I met this dynamic and hard working team at their premises in Valencia, where the heart of the company is beating, modulating microRNAs and developing innovative medicines, tailored to patients’ specific needs. EIC Accelerator blended finance is awarded for the development of a brand new treatment to Myotic Dystrophy Type 1 (DM1), an orphan disease affecting more than 900,000 people worldwide (estimated prevalence 1/8,000). This condition has currently no cure, and no approved treatment. A first-in-class disease modifying therapy, ATX-01, developed by ARTHEx, addresses the cause of DM1 with a dual and unique mechanism of action, which targets micro-RNA-23b a key factor in the disease pathogenesis. ARTHEx biotech is a spin-off biotech company from the University of Valencia. They have grown from 1 person in 2019 when the company was founded to a team of 20 right now. The EIC Accelerator grant is used to support Phase I/IIa clinical trial of ATX-01 for DM1. beatriz llamusi PhD, CSO & Co-Founder of ARTHEx biotech mentioned: “This grant empowers us to bridge the gap between foundational scientific research and clinical application, driving the development of ATX-01 for DM1. With its dual mechanism, we're confident in our potential to set a new standard in treatment within the DM1 space.”   It is simply amazing to see European players raising up to their potential to bring best-in-class treatments in the global fight against rare diseases. To learn more about their approach and pipeline visit ARTHEx Biotech https://lnkd.in/ddBQyg-E #EUeic, #eicAccelerator #MyotonicDystrophy #biotech #financing #microRNA  

Could City Therapeutics revolutionize biotech with $135M and a blueprint from RNAi expert John Maraganore? 💡💊 Exciting news as City Therapeutics takes the biotech world by storm, opening its doors with a hefty $135 million funding, and groundbreaking work led by none other than RNAi expert, John Maraganore Ph.D. A significant force in the RNAi space, Maraganore's involvement promises to give this venture not just robust financial backing but also incredible scientific credibility. Their goal to improve health by developing next-generation therapies is innovative indeed. It's thrilling how quickly transformative technologies like these are breaking ground. Imagine limitless possibilities if science can leverage their efforts successfully! This story represents not just ground-breaking science but also the power of collaboration in our tech-infused world. Let's take this as our cue - we should look for opportunities for innovation & ignite corporate transformation! 🚀 Don't get left behind in this fast-paced race towards advancement; adopt AI solutions & automation to drive growth in your venture today! Book a meeting with us now: https://lnkd.in/gH39iDY3 Become part of our dynamic community of 160K+ corporate decision-makers, investors & groundbreaking founders - collaborating, learning together and transforming strategies into successful ventures! Keep innovating because change is not only coming – it’s here: https://lnkd.in/eEPzmzBR. #CityTherapeutics #JohnMaraganore #RNAiTech #BiotechRevolution #CollaborativeInnovation #NextGenerationTherapies #CorporateTransformation #AIInBusiness #StartupAccess #IgniteInnovation.